Physician profile
Cheryl L Zdana
NPI 1588972954
$1,657.78
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was more than what 82% of Pain Management providers received nationally (typical 2025 total: $52.94).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379 · 2022: $270 · 2023: $236 · 2024: $473 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $316.17 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.89 | 2024 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $143.41 | 2021-2022 | |
| Abbvie INC. | $135.78 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $121.23 | 2021-2022 | |
| Janssen Biotech, INC. | $121.06 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Ardelyx, INC. | $79.76 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $67.83 | 2024-2025 | Dupixent, Libtayo |
| Tactile Systems Technology INC | $58.83 | 2025 | Flexitouch Plus, Nimbl |
| Avanir Pharmaceuticals, INC. | $54.87 | 2022 | |
| Ucb, INC. | $47.48 | 2024-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $33.34 | 2021-2024 | Breztri |
| Idorsia Pharmaceuticals US INC | $30.11 | 2023 | Quviviq |
| Exact Sciences Corporation | $27.46 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $27.28 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $27.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.95 | 2024 | Voquezna |
| Pfizer INC. | $12.18 | 2021 | |
| Boston Scientific Corporation | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Zdana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.